Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population

Catheterization and Cardiovascular Interventions

Volumn 86, Issue 6, 2015, Pages 975-981

  Wiebe, Jens ^a   Gilbert, Florian ^a   Dörr, Oliver ^a   Liebetrau, Christoph ^b   Wilkens, Eva ^a   Bauer, Timm ^a   Elsässer, Albrecht ^c   Möllmann, Helge ^b   Hamm, Christian W ^a,b   Nef, Holger M ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kerckhoff Heart and Thorax Center   (Germany)

^c Clinic for Cardiology/Heart Center Oldenburg   (Germany)

Author keywords

bioabsorbable devices polymers; coronary artery disease; diabetes mellitus; percutaneous coronary intervention

Indexed keywords

ANTIDIABETIC AGENT; EVEROLIMUS; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR PARAMETERS; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IMPLANTATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; TARGET LESION REVASCULARIZATION; TARGET VESSEL FAILURE; BIODEGRADABLE IMPLANT; COHORT ANALYSIS; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; EVALUATION STUDY; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; RADIOGRAPHY; REGISTER; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84947034496     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26140     Document Type: Article

References (24)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619.
3. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
4. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Committee for Practice Guidelines ESC, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL., 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management ofstable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
5. Van Belle E, Périé M, Braune D, Chmaït A, Meurice T, Abolmaali K, McFadden EP, Bauters C, Lablanche JM, Bertrand ME., Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002; 40: 410-417.
6. Mathew V, Holmes DR., Outcomes in diabetics undergoing revascularization: the long and the short of it. J Am Coll Cardiol 2002; 40: 424-427.
7. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW., Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6: 914-22.
8. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S., Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013; 6: 777-789.
9. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA., Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.
10. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, GarcÄ-a-GarcÄ-a HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R., Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2011; 122: 2288-2300.
11. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA., Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9: 1271-1284.
12. Taylor J., Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2506-2507.
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
14. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Mario Di, Colombo C, Capranzano A, Wiebe P, Araszkiewicz J, Geraci A, Pyxaras S, Mattesini S, Naganuma A, Münzel T, Tamburino C., Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014; 20140707-06. pii:
15. Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS., Everolimus-eluting xience v/promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. JACC Cardiovasc Interv 2014; 7: 471-481.
16. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB., The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
17. Kereiakes DJ, Young JJ., Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents. Rev Cardiovasc Med 2005; 6: 48-58.
18. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P., Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
19. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2014; 385: 43-54.
20. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D., A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
21. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM., First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012; 5: 620-632.
22. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW., Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy. Eur Heart J 2012; 33: 1325-1333.
23. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, García-García HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, Stone GW, Abizaid A, Serruys PW;, ABSORB Cohort B, Investigators ABSORB EXTEND Investigators SPIRIT FIRST Investigators, SPIRIT II, Investigators SPIRIT IIIInvestigators SPIRIT IV. Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv 2014; 7: 482-493.
24. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A., Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014; 100: 153-159.